NEW YORK, October 27, 2017 /PRNewswire/ --
If you want a Stock Review on IRWD, MYL, NBIX, or VSAR then come overto http://dailystocktracker.com/register/ and sign up for your free customized report. According to a Research and Markets report titled, "Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022," the
On Thursday, shares in Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc. recorded a trading volume of 1.52 million shares, which was above their three months average volume of 1.21 million shares. The stock ended at $14.57, declining 2.15% from the last trading session. The Company's shares are trading below their 50-day moving average by 6.57%. Furthermore, shares of Ironwood Pharma, which engages in the research, development, and commercialization of human therapeutic products, have a Relative Strength Index (RSI) of 37.44.
On October 19th, 2017, Ironwood Pharma announced that it will host its Q3 2017 investor update conference call and webcast at 8:30 a.m. ET on November 02nd, 2017. The webcast may be accessed under the Investors section of the Company's website. Access our complete research report on IRWD for free at: http://dailystocktracker.com/registration/?symbol=IRWD
Hatfield, the UK-based Mylan N.V.'s stock finished yesterday's session 1.15% lower at $38.57 with a total trading volume of 4.49 million shares. The Company's shares have gained 20.80% in the last one month and 1.10% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 14.65% and 2.88%, respectively. Furthermore, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have an RSI of 67.75.
On October 04th, 2017, research firm BTIG Research reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $42 a share to $45 a share.
On October 17th, 2017, Mylan announced that it will release its financial results for Q3 ended September 30th, 2017, before the open of the US financial markets on November 06th, 2017. The Company will also host a conference call and live webcast at 10:30 a.m. ET that same day to review the results. The briefing can be accessed live on the Company's investor website. The complimentary research report on MYL can be downloaded at: http://dailystocktracker.com/registration/?symbol=MYL
At the close of trading on Thursday, shares in San Diego, California headquartered Neurocrine Biosciences Inc. rose 0.58%, ending the day at $59.35. The stock recorded a trading volume of 819,784 shares. The Company's shares have advanced 1.04% in the last one month, 20.00% in the previous three months, and 53.36% since the start of this year. The stock is trading 2.50% and 20.12% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US and internationally, have an RSI of 51.05.
On October 24th, 2017, Neurocrine Biosciences announced that it will report Q3 2017 results after the NASDAQ market close on November 01st, 2017. The Company will then host a live conference call and webcast at 5:00 p.m. ET to discuss its financial results and provide an update. The call can be accessed on the Company's website. Register for free on DailyStockTracker.com and get access to the latest report on NBIX at: http://dailystocktracker.com/registration/?symbol=NBIX
Menlo Park, California headquartered Versartis Inc.'s shares ended the day 4.17% lower at $2.30 with a total trading volume of 1.11 million shares. The stock is trading 79.37% below its 50-day moving average. Shares of the Company, which operates as an endocrine-focused biopharmaceutical company in the US, have an RSI of 21.89. Download your free research report on VSAR at: http://dailystocktracker.com/registration/?symbol=VSAR
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All